Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) CD markers | Read Reviews & Product Use Citations

Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD.

Quality Control

Cited in Nature Medicine for its top-tier quality
SDS
Datasheet

99

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	7	+++
AB680	1					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53	3				✔
LY-3475070	2					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD.

Product Details

CAS No.	934823-49-1
Molecular Weight	146.5 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07720180	NOT_YET_RECRUITING	Drug: Fludarabine\|Drug: Cyclophosphamide	Ovarian Cancer	Medical University of South Carolina	2026-12-01	PHASE2
NCT07594106	RECRUITING	Drug: REGN15505\|Drug: REGN15505+Cemiplimab\|Drug: REGN15505+R	Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC)	Regeneron Pharmaceuticals	2026-07-20	PHASE1; PHASE2
NCT06378190	RECRUITING		Refractory B-Cell Lymphoma; B-cell Lymphoma Recurrent	Instituto de Investigación Biomédica de Salamanca	2024-03-11	PHASE1; PHASE2
NCT05945849	RECRUITING		Leukemia, Myeloid, Acute	University of Pennsylvania	2024-02-23	PHASE1
NCT06782932	RECRUITING	Drug: AGEN2373\|Drug: Balstilimab\|Drug: Cyclophosphamide\|Drug	Pancreatic Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2025-05-27	PHASE1; PHASE2
NCT07701889	NOT_YET_RECRUITING		Hematologic Diseases	Roswell Park Cancer Institute	2026-10	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.